Position in NTLA
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$6,529,428
+$819,400 QoQ
Shares Held
385,900
-13.4% QoQ
Ownership
0.275%
of shares outstanding
% of Portfolio
3.08%
of 13F equity value
Holder Rank
#49
of 329 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NTLA Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Birchview Capital, LP holds $91,246,272 across 49 Biotechnology names. NTLA ranks #2 (7.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | SLDB |
Solid Biosciences Inc.
|
666,196 | $6,655,298 | |
| 2 | NTLA |
Intellia Therapeutics, Inc.
This page
|
385,900 | $6,529,428 | |
| 3 | STOK |
Stoke Therapeutics, Inc.
|
178,110 | $5,827,759 | |
| 4 | NKTR |
Nektar Therapeutics
|
81,000 | $5,654,610 | |
| 5 | CORT |
Corcept Therapeutics Inc
|
57,200 | $4,973,540 | |
| 6 | PRTA |
Prothena Corp Public Ltd Co
|
449,019 | $4,395,896 | |
| 7 | ACAD |
Acadia Pharmaceuticals Inc
|
171,000 | $4,326,300 | |
| 8 | PTGX |
Protagonist Therapeutics, Inc
|
35,018 | $4,292,506 |
All Filings in NTLA
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $6,529,428 | 385,900 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $5,710,028 | 445,400 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $2,835,446 | 315,400 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $1,036,200 | 60,000 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $562,800 | 60,000 | Shares | Sole | 2025-08-14 | |
| No filing history on record for this holder in this stock. | ||||||